A systematic study of the relationship between the molecular structure of a series of thiol end-capped oligo-phenylenevinylenes (OPVs) and the coherent electronic transmission at the single molecule level was measured by scanning tunneling microscopy (STM). This reveals a significant change in the electronic transparency of various OPV derivatives due to the insertion of a methylene spacer group or due to nitro group substitution. Apparently, changes in the conjugation path through the central benzene ring from para to meta substitution does not have a profound effect on the electronic transparency of the molecules.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/nl050032q | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rationalizing Photophysics of Co(III) Complexes with Pendant Pyrene Moieties.
Inorg Chem
January 2025
Department of Chemistry, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada.
Pendant organic chromophores have been used to improve the photocatalytic performance of many metal-based photosensitizers, particularly in first-row metals, by increasing π conjugation in ligands and lowering the energy of the photoactive absorption band. Using a combination of spectroscopic studies and computational modeling, we rationalize the excited state dynamics of a Co(III) complex containing pendant pyrene moieties, , where = 1,1'-(4-(pyren-1-yl)pyridine-2,6-diyl)bis(3-methyl-1-imidazol-3-ium). displays higher visible absorptivity, and blue luminescence from pyrene singlet excited states compared with [ = 1,1'-(pyridine-2,6-diyl)bis(3-methyl-1-imidazol-3-ium)] in which the pyrene moiety is absent.
View Article and Find Full Text PDFAntibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing.
Curr Oncol Rep
January 2025
Susan F. Smith Center for Women's Cancers, Breast Oncology Program, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA.
Purpose Of Review: In this review, we discuss evidence supporting the use of antibody-drug conjugates (ADCs) in breast cancer treatment, describe novel ADCs and combination regimens under development, and examine our current understanding of resistance mechanisms and biomarkers to guide ADC selection and sequencing.
Recent Findings: Three ADCs have proven benefit in patients with metastatic breast cancer: trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), and sacituzumab govitecan (SG). There are over two hundred investigational ADCs on the horizon, as pre-clinical studies work to identify novel ADC targets and structures.
The spatially informed mFISHseq assay resolves biomarker discordance and predicts treatment response in breast cancer.
Nat Commun
January 2025
MultiplexDX, s.r.o., Comenius University Science Park, Bratislava, Slovakia.
Current assays fail to address breast cancer's complex biology and accurately predict treatment response. On a retrospective cohort of 1082 female breast tissues, we develop and validate mFISHseq, which integrates multiplexed RNA fluorescent in situ hybridization with RNA-sequencing, guided by laser capture microdissection. This technique ensures tumor purity, unbiased whole transcriptome profiling, and explicitly quantifies intratumoral heterogeneity.
View Article and Find Full Text PDFLigand Inter-Relation Analysis Via Graph Theory Predicts Macrophage Response.
Adv Mater
December 2024
Department of Materials Science and Engineering, Korea University, Seoul, 02841, Republic of Korea.
Graph theory has been widely used to quantitatively analyze complex networks of molecules, materials, and cells. Analyzing the dynamic complex structure of extracellular matrix can predict cell-material interactions but has not yet been demonstrated. In this study, graph theory-based mathematical modeling of RGD ligand graph inter-relation is demonstrated by differentially cutting off RGD-to-RGD interlinkages with flexibly conjugated magnetic nanobars (MNBs) with tunable aspect ratio.
View Article and Find Full Text PDFAdvances in DLL3-targeted therapies for small cell lung cancer: challenges, opportunities, and future directions.
Front Oncol
December 2024
Taylor's University, Subang Jaya, Selangor, Malaysia.
Small cell lung cancer (SCLC) remains one of the most aggressive and challenging malignancies to treat, with limited therapeutic options and poor outcomes. Recent advances in understanding SCLC biology have identified Delta-like ligand 3 (DLL3) as a promising target for novel therapies. This review explores the evolving landscape of DLL3-targeted therapies in SCLC, examining their mechanistic basis, preclinical promise, and clinical development.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!